Explore
Trendline
Sanofi Reportedly Explores Acquisition of Insmed Amidst Post-Dupixent Strategy
Sanofi Reportedly Explores Acquisition of Insmed Amidst Post-Dupixent Strategy
Read More
Trendline
Sanofi Seeks Area Business Manager for Hematology/Oncology in Omaha, NE, to Drive Specialty Drug Sales
Sanofi Seeks Area Business Manager for Hematology/Oncology in Omaha, NE, to Drive Specialty Drug Sales
Read More
Trendline
Big Pharma Accelerates Drug Discovery Timelines with AI Integration
Big Pharma Accelerates Drug Discovery Timelines with AI Integration
Read More
Trendline
Novartis Projects Slowed Growth Through 2031, Emphasizing Pipeline Potential Amid Patent Expiries
Novartis Projects Slowed Growth Through 2031, Emphasizing Pipeline Potential Amid Patent Expiries
Read More
Trendline
Regeneron Pharmaceuticals Defies Skeptics with Strong Performance and Clinical Milestones
Regeneron Pharmaceuticals Defies Skeptics with Strong Performance and Clinical Milestones
Read More
Trendline
AI Accelerates Early-Stage Drug Development for Major Pharmaceutical Companies
AI Accelerates Early-Stage Drug Development for Major Pharmaceutical Companies
Read More
Trendline
Hogan Lovells Cadwalader Advises Gedeon Richter on Acquisition of Mayne Pharma, Expanding Women's Health Focus in U.S.
Hogan Lovells Cadwalader Advises Gedeon Richter on Acquisition of Mayne Pharma, Expanding Women's Health Focus in U.S.
Read More
Trendline
Novartis CEO Warns US Biotech Investment Curbs in China Could Impede Drug Development
Novartis CEO Warns US Biotech Investment Curbs in China Could Impede Drug Development
Read More
Trendline
Eli Lilly Expands Oncology Research Platform with Calytrix Bio Acquisition and Stipple Bio Partnership
Eli Lilly Expands Oncology Research Platform with Calytrix Bio Acquisition and Stipple Bio Partnership
Read More
Reuters
Sanofi's pill becomes first US-approved drug for rare neurological disorder
Nov 18 (Reuters) - The US FDA on Wednesday approved Sanofi's oral drug venglustat, the first treatment approved for a type of rare genetic condition affecting the brain and nervous system.
Read More
Trendline
Pfizer Enters Autoimmune CAR T Therapy Market with $2.6 Billion Deal with China's Starna Therapeutics
Pfizer Enters Autoimmune CAR T Therapy Market with $2.6 Billion Deal with China's Starna Therapeutics
Read More
Trendline
Pfizer CEO Albert Bourla Warns of Chinese Biotech Threat, Advocates AI for Efficiency
Pfizer CEO Albert Bourla Warns of Chinese Biotech Threat, Advocates AI for Efficiency
Read More